ALKS — Alkermes plc

Summary of Alkermes Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $392.9 million, driven by a 38% year-over-year increase in net sales from proprietary products to $338.1 million.
• Net Sales Breakdown:
  • VIVITROL: $112.4 million
  • ARISTADA: $93.8 million
  • LYBALVI: $92.4 million (32% year-over-year growth)
  • LUMRYZ: $72 million (6 weeks of contribution post-acquisition)
• GAAP Net Loss: $66.5 million; Adjusted EBITDA: $80.3 million, exceeding prior expectations of $30 million to $50 million.
• Cash Position: Approximately $538 million in cash and investments; $775 million used for the Avadel acquisition.

2. Strategic Updates and Business Highlights

• Acquisition of Avadel Pharmaceuticals: Completed in mid-February, adding LUMRYZ, a sodium oxybate treatment for narcolepsy, to Alkermes' portfolio. This acquisition is seen as a strategic move to establish a presence in the sleep medicine market.
• Commercial Expansion: Alkermes now has capabilities in addiction, psychiatry, and sleep medicine, with a focus on building relationships with sleep specialists.
• Orexin Program Development: Emphasis on advancing Alixorexton for narcolepsy and idiopathic hypersomnia, with ongoing Phase III studies and plans to expand into ADHD and fatigue-related conditions.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • VIVITROL: Expected net sales of $460 million to $480 million.
  • ARISTADA: Expected net sales of $365 million to $385 million.
  • LYBALVI: Expected net sales of $380 million to $400 million.
  • LUMRYZ: Expected total net sales of $350 million to $370 million.
  • Adjusted EBITDA: Expected to be in the range of $100 million to $120 million for Q2, with full-year adjusted EBITDA projected to exceed $370 million.
• Debt Management: Plans to pay down $1.525 billion in term loans quickly with cash flows from operations.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Eli Lilly's entry into the orexin therapeutic space raises concerns about competition. The company is closely monitoring the impact of generic sodium oxybate products on LUMRYZ.
• Market Dynamics: Potential price pressure from non-AG generic sodium oxybate could affect LUMRYZ's performance, although current demand remains strong.
• Cost Management: Increased R&D expenses ($103.3 million) due to ongoing clinical trials, which may impact profitability in the short term.

5. Notable Q&A Insights

• ADHD Development: Alkermes is initiating a Phase Ib study for ALKS 7290 in adults with ADHD, with plans for a larger Phase II study later in the year. Preclinical data shows potential for efficacy comparable to stimulants.
• LUMRYZ and IH: The upcoming Phase III REVITALYZ study for LUMRYZ in idiopathic hypersomnia is expected to provide significant data, with a potential launch in 2028 if approved.
• Patient Mix for LUMRYZ: The company anticipates a mix of new patients and switches from existing oxybate therapies, with a focus on expanding market access.
• Long-Term Strategy: Alkermes remains open to various strategic options, including potential asset sales, but is focused on advancing its pipeline and enhancing shareholder value.

Overall, Alkermes reported strong financial performance in Q1 2026, driven by robust sales across its product portfolio and strategic acquisitions, while navigating competitive pressures and planning for future growth in the sleep medicine and ADHD markets.